Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

This is an interventional treatment trial for Hodgkin Lymphoma Read More

Inclusion Criteria:

• Age ≥ 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
• Biopsy proven relapsed or refractory cHL
• Prior treatment with at least two systemic therapies
• Metabolically active measurable disease by PET imaging per the 2014 Lugano criteria
• Hemoglobin ≥ 9.5 g/dL
• Absolute neutrophil count ≥ 1,000 cells/μL without G-CSF support within 3 weeks prior to enrollment
• Platelet count ≥ 75,000 cells/μL
• Creatinine clearance > 40 mL/min per the Cockroft-Gault formula
• Total bilirubin < 1.5 x upper limit of normal (ULN) (or < 3.0 x ULN and primarily unconjugated in subjects with a history of Gilbert's syndrome)
• Negative urine or serum pregnancy test within 30 days of enrollment and within 72 hours before the first administration of magrolimab for women of childbearing potential
• Women of childbearing potential must be willing to use at least 1 highly effective method of contraception during the study and continue for 4 months after the last dose of magrolimab
• Male subjects who are sexually active with a woman of childbearing potential and who have not had vasectomies must be willing to use a barrier method of contraception during the study and for 4 months after the last dose of magrolimab
• Ability to understand and the willingness to sign the written IRB approved informed consent document
• Must be willing and able to comply with the clinic visits and procedures outlined in the study protocol

Exclusion Criteria:

• Prior treatment with a PD-1 inhibitor within 6 months prior to enrollment
• Prior treatment with antibodies targeting CD47 or SIRPα2
• Prior allogeneic hematopoietic cell transplantation
• Systemic autoimmune disorder on chronic immunosuppression (defined as ≥ 10 mg of prednisone daily)
• RBC transfusion dependence, defined as requiring more than 2 units of RBCs during the 4-week period prior to screening
• History of hemolytic anemia, autoimmune thrombocytopenia, or Evan's syndrome within the last 3 months
• Second malignancy not in complete remission for at least 1 year, excluding fully resected non melanoma skin cancer or localized prostate cancer
• Women who are pregnant or breast feeding
• HIV or hepatitis B or C infection with active viral replication by PCR
• Second malignancy not in complete remission for at least 1 year, excluding fully resected non-melanoma skin cancer or localized prostate cancer
• Active cardiac disease including unstable angina, decompensated congestive heart failure, or severe uncontrolled conduction abnormalities
• History of non-infectious pneumonitis requiring corticosteroids or current pneumonitis
• Significant medical conditions, as assessed by the investigators and IND holder, that would substantially increase the risk benefit ratio of participating in the study
• History of psychiatric illness or substance abuse likely to interfere with ability to comply with protocol requirements
• Received a live or live attenuated vaccine within 30 days before the first dose of study intervention
• Received any anti-cancer therapy within 2 weeks prior to the first dose of study intervention